Ladenburg Thalmann initiated coverage on shares of Viveve Medical Inc (NASDAQ:VIVE) in a research note published on Tuesday morning. The brokerage issued a buy rating on the stock.

Separately, Maxim Group reaffirmed a buy rating and issued a $11.00 target price (down from $16.00) on shares of Viveve Medical in a research note on Tuesday, June 21st.

Shares of Viveve Medical (NASDAQ:VIVE) opened at 7.21 on Tuesday. Viveve Medical has a 12-month low of $4.02 and a 12-month high of $10.50. The company’s market cap is $76.47 million. The firm has a 50-day moving average of $7.61 and a 200-day moving average of $6.61.

Viveve Medical (NASDAQ:VIVE) last issued its earnings results on Thursday, August 11th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.48) by $0.18. The company had revenue of $1.56 million for the quarter, compared to the consensus estimate of $1.33 million. Analysts predict that Viveve Medical will post ($2.06) EPS for the current year.

Viveve Medical Company Profile

Viveve Medical, Inc, formerly PLC Systems, Inc, designs, develops, manufactures and markets medical devices for the non-invasive treatment of vaginal laxity. The Company’s Viveve Treatment is a non-invasive solution for vaginal laxity that is performed in approximately 30 minutes, in a physician’s office.

5 Day Chart for NASDAQ:VIVE

Receive News & Ratings for Viveve Medical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.